CAPRICOR THERAPEUTICS INC (CAPR) Fundamental Analysis & Valuation

NASDAQ:CAPR • US14070B3096

30.63 USD
+2.73 (+9.78%)
At close: Mar 9, 2026
30.95 USD
+0.32 (+1.04%)
After Hours: 3/9/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CAPR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, CAPR scores 3 out of 10 in our fundamental rating. CAPR was compared to 519 industry peers in the Biotechnology industry. While CAPR has a great health rating, there are worries on its profitability. CAPR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. CAPR Profitability Analysis

1.1 Basic Checks

  • In the past year CAPR has reported negative net income.
  • In the past year CAPR has reported a negative cash flow from operations.
  • In the past 5 years CAPR always reported negative net income.
  • CAPR had negative operating cash flow in 4 of the past 5 years.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of CAPR (-64.85%) is worse than 60.12% of its industry peers.
  • CAPR has a Return On Equity of -97.76%. This is comparable to the rest of the industry: CAPR outperforms 46.63% of its industry peers.
Industry RankSector Rank
ROA -64.85%
ROE -97.76%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CAPR Health Analysis

2.1 Basic Checks

  • CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CAPR has been increased compared to 1 year ago.
  • The number of shares outstanding for CAPR has been increased compared to 5 years ago.
  • Compared to 1 year ago, CAPR has an improved debt to assets ratio.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CAPR has an Altman-Z score of 13.45. This indicates that CAPR is financially healthy and has little risk of bankruptcy at the moment.
  • CAPR's Altman-Z score of 13.45 is amongst the best of the industry. CAPR outperforms 84.78% of its industry peers.
  • There is no outstanding debt for CAPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.45
ROIC/WACCN/A
WACC8.78%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • CAPR has a Current Ratio of 3.59. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CAPR (3.59) is comparable to the rest of the industry.
  • A Quick Ratio of 3.59 indicates that CAPR has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.59, CAPR is in line with its industry, outperforming 44.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.59
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CAPR Growth Analysis

3.1 Past

  • The earnings per share for CAPR have decreased strongly by -69.81% in the last year.
  • The Revenue for CAPR has decreased by -52.08% in the past year. This is quite bad
  • Measured over the past years, CAPR shows a very strong growth in Revenue. The Revenue has been growing by 85.64% on average per year.
EPS 1Y (TTM)-69.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.11%
Revenue 1Y (TTM)-52.08%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, CAPR will show a very strong growth in Earnings Per Share. The EPS will grow by 41.69% on average per year.
  • The Revenue is expected to grow by 90.58% on average over the next years. This is a very strong growth
EPS Next Y-83.41%
EPS Next 2Y-14.49%
EPS Next 3Y27.38%
EPS Next 5Y41.69%
Revenue Next Year-96.42%
Revenue Next 2Y149.49%
Revenue Next 3Y101.72%
Revenue Next 5Y90.58%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. CAPR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CAPR's earnings are expected to grow with 27.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.49%
EPS Next 3Y27.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CAPR Dividend Analysis

5.1 Amount

  • No dividends for CAPR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAPR Fundamentals: All Metrics, Ratios and Statistics

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (3/9/2026, 8:00:02 PM)

After market: 30.95 +0.32 (+1.04%)

30.63

+2.73 (+9.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-25
Inst Owners67.85%
Inst Owner Change88.98%
Ins Owners1.16%
Ins Owner Change0.02%
Market Cap1.40B
Revenue(TTM)11.13M
Net Income(TTM)-81.99M
Analysts83.75
Price Target51.82 (69.18%)
Short Float %17.43%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.94%
Min EPS beat(2)-19.18%
Max EPS beat(2)3.3%
EPS beat(4)2
Avg EPS beat(4)-9.88%
Min EPS beat(4)-64.08%
Max EPS beat(4)40.43%
EPS beat(8)4
Avg EPS beat(8)-16.23%
EPS beat(12)8
Avg EPS beat(12)-6.77%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-51.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)92.08%
Revenue beat(8)3
Avg Revenue beat(8)-34.76%
Revenue beat(12)7
Avg Revenue beat(12)1598.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)32.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.07%
EPS NY rev (1m)0%
EPS NY rev (3m)0.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 125.82
P/FCF N/A
P/OCF N/A
P/B 16.7
P/tB 16.7
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.24
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.85%
ROE -97.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 416.19%
Cap/Sales 65.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.59
Altman-Z 13.45
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.11%
EPS Next Y-83.41%
EPS Next 2Y-14.49%
EPS Next 3Y27.38%
EPS Next 5Y41.69%
Revenue 1Y (TTM)-52.08%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%
Revenue Next Year-96.42%
Revenue Next 2Y149.49%
Revenue Next 3Y101.72%
Revenue Next 5Y90.58%
EBIT growth 1Y-139.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-127.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-191.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-192.06%
OCF growth 3YN/A
OCF growth 5YN/A

CAPRICOR THERAPEUTICS INC / CAPR FAQ

What is the fundamental rating for CAPR stock?

ChartMill assigns a fundamental rating of 3 / 10 to CAPR.


What is the valuation status of CAPRICOR THERAPEUTICS INC (CAPR) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAPRICOR THERAPEUTICS INC (CAPR). This can be considered as Overvalued.


What is the profitability of CAPR stock?

CAPRICOR THERAPEUTICS INC (CAPR) has a profitability rating of 0 / 10.